Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

H3 Opens Labs In Cambridge, Mass.

by Michael McCoy
December 12, 2011 | A version of this story appeared in Volume 89, Issue 50

[+]Enlarge
Credit: H3 Biomedicine
Eisai CEO Haruo Naito (left) and H3 CEO Markus Warmuth tour H3’s new labs.
Pictured: Haruo Naito, President & CEO of Eisai Co. Ltd. of Japan (left), and Markus Warmuth, M.D., President & CEO of H3 Biomedicine Inc. at H3 laboratories in Cambridge, MA.
Credit: H3 Biomedicine
Eisai CEO Haruo Naito (left) and H3 CEO Markus Warmuth tour H3’s new labs.

H3 Biomedicine has opened new headquarters and 24,000 sq ft of lab space in Cambridge, Mass. Launched in January, the small-molecule oncology drug firm plans to increase its staff to 70 people over the next year. H3’s scientific founders are Stuart Schreiber and Todd Golub of the Broad Institute of Harvard University and MIT. H3 is backed by the Japanese drug company Eisai, which has pledged up to $200 million in research funding to H3.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.